Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Moodys
Boehringer Ingelheim
Baxter
AstraZeneca

Last Updated: December 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DALFAMPRIDINE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for dalfampridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01215084 ↗ A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers Completed Acorda Therapeutics Phase 1 2010-10-01 The primary objective of the study is to determine the Pharmacokinetic (PK) and safety profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers. The secondary objective of this study is to compare the PK and safety profiles of fampridine-PR 10 mg among the Chinese, Japanese, and Caucasian adult healthy volunteers.
NCT01215084 ↗ A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers Completed Biogen Phase 1 2010-10-01 The primary objective of the study is to determine the Pharmacokinetic (PK) and safety profiles of fampridine-PR 10 mg in Chinese and Japanese adult healthy volunteers. The secondary objective of this study is to compare the PK and safety profiles of fampridine-PR 10 mg among the Chinese, Japanese, and Caucasian adult healthy volunteers.
NCT01235221 ↗ Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. Completed Acorda Therapeutics Phase 3 2010-12-01 The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB041 (fampridine-sustained release (SR)) treatment in Canadian participants with multiple sclerosis (MS) who previously participated in the registrational and extension studies conducted by Acorda. Those studies include NCT00654927 (MS-F202EXT), NCT00648908 (MS-F203EXT) and NCT00649792 (MS-F204EXT).
NCT01235221 ↗ Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials. Completed Biogen Phase 3 2010-12-01 The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB041 (fampridine-sustained release (SR)) treatment in Canadian participants with multiple sclerosis (MS) who previously participated in the registrational and extension studies conducted by Acorda. Those studies include NCT00654927 (MS-F202EXT), NCT00648908 (MS-F203EXT) and NCT00649792 (MS-F204EXT).
NCT01316055 ↗ Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment Completed Acorda Therapeutics Phase 1 2011-01-01 The steady-state pharmacokinetics of Dalfampridine-ER (extended release) 7.5 mg (milligram) tablets in healthy adult volunteers and those with mild and moderate renal impairment, and examine between group comparisons.
NCT01328379 ↗ Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis Completed Acorda Therapeutics Phase 3 2011-03-01 The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.
NCT01337986 ↗ Ampyra for Optic Neuritis in Multiple Sclerosis Completed Acorda Therapeutics Phase 2/Phase 3 2011-05-01 Fifty subjects will be enrolled in this Phase II, investigator-initiated, randomized and blinded cross-over trial of dalfampridine of 8 weeks duration The study will test the hypothesis that dalfampridine, when administered to subjects with incomplete visual recovery after optic neuritis from MS, will result in symptomatic improvement in visual function. The study will consist of one screening/baseline visit, one visit during treatment with active drug, and one visit on placebo. After the baseline visit, subjects will be randomly assigned to receive study medication or placebo for the first three weeks, followed by a two week wash-out, and then treatment reallocation for the latter three weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for dalfampridine

Condition Name

Condition Name for dalfampridine
Intervention Trials
Multiple Sclerosis 12
Transverse Myelitis 2
Myelitis NOS 2
Fatigue 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for dalfampridine
Intervention Trials
Sclerosis 12
Multiple Sclerosis 12
Ischemia 4
Cerebral Infarction 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for dalfampridine

Trials by Country

Trials by Country for dalfampridine
Location Trials
United States 146
Canada 15
France 14
United Kingdom 13
Germany 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for dalfampridine
Location Trials
Florida 10
New York 9
California 8
Massachusetts 7
Michigan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for dalfampridine

Clinical Trial Phase

Clinical Trial Phase for dalfampridine
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2/Phase 3 4
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for dalfampridine
Clinical Trial Phase Trials
Completed 24
Recruiting 2
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for dalfampridine

Sponsor Name

Sponsor Name for dalfampridine
Sponsor Trials
Acorda Therapeutics 17
Biogen 6
Johns Hopkins University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for dalfampridine
Sponsor Trials
Industry 23
Other 19
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKesson
Boehringer Ingelheim
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.